Advertisement
New Zealand markets closed
  • NZX 50

    12,457.41
    -34.17 (-0.27%)
     
  • NZD/USD

    0.6342
    +0.0013 (+0.20%)
     
  • NZD/EUR

    0.5675
    +0.0018 (+0.31%)
     
  • ALL ORDS

    8,476.80
    +14.00 (+0.17%)
     
  • ASX 200

    8,212.20
    +8.50 (+0.10%)
     
  • OIL

    68.64
    +0.97 (+1.43%)
     
  • GOLD

    2,680.80
    -14.10 (-0.52%)
     
  • NASDAQ

    20,008.62
    -106.91 (-0.53%)
     
  • FTSE

    8,320.76
    +35.85 (+0.43%)
     
  • Dow Jones

    42,313.00
    +137.89 (+0.33%)
     
  • DAX

    19,473.63
    +235.27 (+1.22%)
     
  • Hang Seng

    20,632.30
    +707.72 (+3.55%)
     
  • NIKKEI 225

    39,829.56
    +903.93 (+2.32%)
     
  • NZD/JPY

    90.1570
    -1.4180 (-1.55%)
     

Privia Health Group Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Privia Health Group (NASDAQ:PRVA) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$422.3m (up 2.2% from 2Q 2023).

  • Net income: US$3.47m (down 52% from 2Q 2023).

  • Profit margin: 0.8% (down from 1.8% in 2Q 2023). The decrease in margin was driven by higher expenses.

  • EPS: US$0.029 (down from US$0.063 in 2Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Privia Health Group Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 35%.

Looking ahead, revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 4.6% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Privia Health Group that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.